-

SolarEdge Technologies, Inc. (SEDG) Shareholder Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against SolarEdge Technologies, Inc.

SAN DIEGO--(BUSINESS WIRE)--The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired common shares of SolarEdge Technologies, Inc. (NASDAQ: SEDG) stock between August 6, 2022 and October 19, 2022.

What Now: Similarly situated shareholders may be eligible to participate in the class action against SolarEdge. Shareholders who want to be appointed lead plaintiff for the class must file their papers by January 3, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

What is this Case About: SolarEdge Technologies, Inc. (SEDG) is Accused of Misappropriating its Patented Technology

According to the complaint, during the class period, defendants failed to disclose to investors that the designs of the power optimizers, inverters, and components thereof used to develop SolarEdge’s products potentially originated with and were misappropriated from Ampt LLC (“Ampt”), a competitor in the renewable energy industry. On July 28, 2022, Ampt filed a complaint in the U.S. District Court for the District of Delaware and with the U.S. International Trade Commission (“ITC”) making such allegations.

On August 29, 2022, the ITC issued a statement that it had voted to investigate the allegations made by Ampt. On this news, the price of SolarEdge shares declined 1.4% to close at $279.46 on August 29, 2022, causing SolarEdge to lose market capitalization of $265 million on August 29, 2022.

Then, on October 19, 2022, Judge Connolly stayed the parallel proceeding filed against SolarEdge by Ampt, indicating that the findings of the ITC will likely have a direct impact on the court proceedings. On this news, shares of SolarEdge stock fell 2.3% to close at $199.46 on October 19, 2022.

A ruling against SolarEdge could prohibit the import, marketing, and sale of its power optimizers and inverters, including solar energy systems that contain such products, which in turn seriously threaten SolarEdge’s ability to monetize on their solar energy systems that contain the power optimizers and inverters in the United States and generate revenue.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against SolarEdge Technologies, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:SEDG

Release Summary
SolarEdge Technologies, Inc. (SEDG) is Accused of Misappropriating its Patented Technology
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom